GNTA.OB...Sector: Healthcare...Industry: Biotechnology & Drugs

[higherstocks]

Up 5% in premarket.  I dont think much of a pull back is coming.  Today could be the fda news.  We will see

[setravis]

GENTA INC (NasdaqNM:GNTA) Delayed quote data 

Last Trade: 2.48
Trade Time: 9:53AM ET
Change:  0.05 (2.06%) 
Prev Close: 2.43
Open: 2.50
Bid: 2.48 x 7900 
Ask: 2.48 x 400 
1y Target Est: N/A

  Day's Range: 2.42 - 2.55
52wk Range: 0.75 - 2.45
Volume: 2,298,661
Avg Vol (3m): 3,217,070
Market Cap: 283.75M
P/E (ttm): 10.42
EPS (ttm): 0.24
Div & Yield: N/A (N/A)

[higherstocks]

Looking good so far hopefully we can get a close of HOD and news out after hours. 

[higherstocks]

GNTA Still Flying High.    $12-$15 coming soon. 

[setravis]

If this one can push over $3.00,Then it could be an indication something is about to happen.
One more positive mention, or any good news, and this one could get over the $5.00 mark.
All IMHO of course.....

Technicals
Record Price High
Most Actives

Last Price Quote is:
33.77%above 13-day EMA
64.93%above 50-day EMA
RS Rating: 97 

Fundamentals
Key Data:
Market Cap (M): $251.72 
P/E Ratio: 8.20 
PEG Ratio: N/A 
Next Earnings: 02/16/2006
Last Analyst Rating: Hold

[setravis]

Here is a chart with the whole history of GNTA.
Notice the gap at 7.75. I think we will return there.When? I don't know !
Sooner than later I hope.......

Do give ours an Applaud for the fine Stock Pick!

[higherstocks]

Hey setTravis, actulaully this post was from awhile back the other post is more recent to the pick at buy 1.60.  Much more fundamentals on other post.  Maybe Ransburg could merge.

[higherstocks]

Yahoo!   My Yahoo!   Mail     Make Yahoo! your home page   
Sign In
New User?Sign Up
Finance Home - Help 



HomeInvestingNews & CommentaryRetirement & PlanningBanking & CreditLoansTaxesSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search

     

Press Release Source: Genta Incorporated


Genasense(R) Marketing Authorization Application in Melanoma Accepted for Review by European Regulatory Agency
Wednesday February 1, 3:37 pm ET


BERKELEY HEIGHTS, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced that the Company has received notice from the European Medicines Agency (EMEA) that its Marketing Authorization Application (MAA) for Genasense® (oblimersen) has been validated for review by the Agency, which signals the start of the scientific assessment procedure. The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, particularly for patients for normal baseline levels of serum lactate dehydrogenase (LDH). Summary data that support this application can be viewed at: http://www.genta.com .
ADVERTISEMENT


About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com .

This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2004.

[camaaron]

News is out, hold or sell? could you please me decide.

[higherstocks]

Hold Hold Hold.  Thats all I got to say!    This stock whithout the news should be between 12-15.  Unless we have any bad news about the drug the stock will not fall.

[setravis]

That's correct, this thread was started first.The Stock Pick made by Ours,
on 09 May 2005. This is the thread that I have been posting my comments to since I took a postion in the stock.

When Adam started that thread of his on GNTA. It went like this.....

« on: September 20, 2005, 11:33:57 AM »   
GNTA is this a buy 1.62??
Is this a buy

Instead of starting a new thread he could have place that question of his to the thread that was up and running. If traders post to the thread that already exist that keeps all our comments in one thread with lot's of info at the tip of your fingers.
I think stocks here with more that one thread should all be merged with the first thread that was started.Some have so many threads started, a lot of times I have to find the thread that I was posting my comments to. I have seen traders here post a comment about a stock. And the next day if they have something else to say about the same stock, they will start another thread with just that one comment. If all of our comments here are kept on one thread on a certain stock pick, then you can see the history of a pick all in one place. IMHO.....

[setravis]

GENTA INC (NasdaqNM:GNTA) Delayed quote data 

Pre-Market (RT-ECN): 2.86  0.10 (3.62%) 

[higherstocks]

Yahoo!   My Yahoo!   Mail     Make Yahoo! your home page   
Sign In
New User?Sign Up
Finance Home - Help 



HomeInvestingNews & CommentaryRetirement & PlanningBanking & CreditLoansTaxesSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search

     

Press Release Source: Genta Incorporated


Analysis of Genasense(R) Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
Thursday February 2, 8:00 am ET 
Multivariate Analysis Presented in Paris Defines Role of Prognostic Factors in Largest Randomized Trial


BERKELEY HEIGHTS, N.J., Feb. 2 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced the presentation of analyses that confirmed the major efficacy variables from the Company's randomized Phase 3 trial of Genasense® (oblimersen) plus chemotherapy in patients with advanced metastatic melanoma. The data were presented in Paris, France at the 17th International Congress on Anticancer Treatment by Dr. Alexander Eggermont from the Daniel den Hoed Cancer Center, Erasmus University, Rotterdam, The Netherlands. Dr. Eggermont is the current president of the European Organization on Research and Treatment of Cancer (EORTC).
ADVERTISEMENT


Recent studies conducted by the EORTC and other groups have shown that elevation of serum lactate dehydrogenase (LDH), a routine blood test, is the most powerful predictor of poor outcome in patients with advanced melanoma. The Genasense study -- the largest randomized trial ever conducted in patients with advanced melanoma -- randomly assigned 771 patients to receive standard chemotherapy using dacarbazine with or without Genasense. Prior to randomization, patients were stratified on the basis of performance status, sites of metastatic disease, and baseline levels of LDH.

Consistent with prior studies, the multivariate analysis confirmed that each of the three stratification factors was significantly correlated with survival in the Genasense trial, whether examined alone or in a Cox multivariate model. However, LDH was the only factor that showed a statistically significant interaction with treatment. Furthermore, the analysis also showed that Genasense was significantly superior to chemotherapy alone in major efficacy variables after accounting for prognostic factors. The maximal benefit of Genasense was observed in patients without elevation in baseline LDH, a group that comprised approximately two-thirds of the study population, or more than 500 patients.

The analysis of this trial with a minimum follow-up of 24 months on all patients comprised the basis of a Marketing Authorization Application (MAA) that has been submitted to the European Medicines Agency (EMEA). A summary of safety and efficacy data from the MAA can be viewed at the Company's website: http://www.genta.com . An earlier analysis of this trial based on a minimum followup of 6 months comprised the basis of a New Drug Application in the U.S. that was withdrawn by Genta in 2004.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The Company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The leading drug in Genta's small molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com .

This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report/Form 10-K for 2004.




--------------------------------------------------------------------------------
Source: Genta Incorporated

[setravis]

Moved up some more in the pre-market...

GENTA INC (NasdaqNM:GNTA) Delayed quote data 

Pre-Market (RT-ECN): 3.20  0.44 (15.94%)  Volume @......1,485,909

[Holygrale]

Jumped in for 10k shares at 3.10.............This one is flying...........